Human DBP adenoviral particles

The human DBP gene encodes D-site binding protein (DBP), a member of the PAR bZIP (proline- and acidic amino acid-rich basic leucine zipper) transcription factor family, responsible for regulating circadian rhythm output pathways. DBP binds to typical D-box promoter elements, driving the rhythmic transcription of numerous downstream genes, particularly in metabolically active tissues such as the liver and kidneys. Its basic region-leucine zipper domain mediates sequence-specific DNA binding and dimerization, enabling it to form homodimers and heterodimers with related factors such as HLF and TEF. DBP expression is tightly regulated by circadian rhythms, typically peaking in a time-dependent manner downstream of the core CLOCK-BMAL1 complex, and acting as a key amplifier that translates clock oscillations into tissue-specific transcriptional programs. Functionally, DBP is involved in regulating various aspects of xenobiotic detoxification enzymes, energy metabolism, hormone synthesis, and sleep-wake homeostasis.

Human DBP adenovirus particles are recombinant, replication-deficient adenoviral vectors used to deliver and transiently overexpress human DBP cDNA in mammalian cells and in vivo. These particles enable rapid, transient, and titratable gain-of-function studies without genomic integration, making them ideal for dissecting circadian rhythm output pathways under temporal control. In vitro, they can be used to explore how elevated DBP levels reshape D-box-driven transcriptional programs, map gene regulatory networks in hepatocytes or other clock-related cells, and combine DBP overexpression with reporter gene assays for enhancer validation and pathway discovery. In pharmacology and toxicology, DBP adenovirus particles can be used to assess clock-dependent regulation of drug-metabolizing enzymes, transporter genes, and nuclear receptors, informing chronotherapy strategies and drug timing. In disease-related research, they can facilitate the modeling of metabolic and sleep-related phenotypes by modulating DBP levels in cells or tissues involved in glucose metabolism, lipid metabolism, or neuronal excitability.